Takeda’s Maribavir For Post-Transplant Cytomegalovirus Might See Split Panel Vote

First-in-class CMV treatment showed better efficacy in refractory patients with genetic resistance than those without; US FDA advisory committee will separately consider benefit-risk in each type of patient. On the safety side, taste disturbance is the only adverse event that stands out.